2 Reasons to be Optimistic About Biogen’s Alzheimer’s Drug

Biogen (NASDAQ:BIIB) shocked investors last year when it said it would submit its investigational Alzheimer's drug to the Food and Drug Administration for approval -- months after halting studies that showed the drug didn't work.

The biotech company explained its decision to file in early 2020 for regulatory approval, saying a look at broader data renewed its belief in aducanumab.